BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Garcia-Tsao G, Bosch J, Kayali Z, Harrison SA, Abdelmalek MF, Lawitz E, Satapathy SK, Ghabril M, Shiffman ML, Younes ZH, Thuluvath PJ, Berzigotti A, Albillos A, Robinson JM, Hagerty DT, Chan JL, Sanyal AJ; IDN-6556-14 Investigators(‡). Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. J Hepatol 2020;72:885-95. [PMID: 31870950 DOI: 10.1016/j.jhep.2019.12.010] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 14.3] [Reference Citation Analysis]
Number Citing Articles
1 Selicean S, Wang C, Guixé-Muntet S, Stefanescu H, Kawada N, Gracia-Sancho J. Regression of portal hypertension: underlying mechanisms and therapeutic strategies. Hepatol Int 2021;15:36-50. [PMID: 33544313 DOI: 10.1007/s12072-021-10135-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Al Attar A, Antaramian A, Noureddin M. Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis. Expert Rev Clin Pharmacol 2021;14:457-64. [PMID: 33612037 DOI: 10.1080/17512433.2021.1894127] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Rinella ME, Noureddin M. STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus. J Hepatol 2020;73:9-11. [PMID: 32360996 DOI: 10.1016/j.jhep.2020.04.034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
4 Luci C, Bourinet M, Leclère PS, Anty R, Gual P. Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies. Front Endocrinol (Lausanne) 2020;11:597648. [PMID: 33384662 DOI: 10.3389/fendo.2020.597648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
5 Berardo C, Di Pasqua LG, Cagna M, Richelmi P, Vairetti M, Ferrigno A. Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research. Int J Mol Sci 2020;21:E9646. [PMID: 33348908 DOI: 10.3390/ijms21249646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
6 Gao Y, Tian R, Liu H, Xue H, Zhang R, Han S, Ji L, Huang W, Zhan J, You Y. Research progress on intervention effect and mechanism of protocatechuic acid on nonalcoholic fatty liver disease. Crit Rev Food Sci Nutr 2021;:1-23. [PMID: 34142875 DOI: 10.1080/10408398.2021.1939265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Li J, Tuo B. Current and Emerging Approaches for Hepatic Fibrosis Treatment. Gastroenterol Res Pract 2021;2021:6612892. [PMID: 34326871 DOI: 10.1155/2021/6612892] [Reference Citation Analysis]
8 Caligiuri A, Gentilini A, Pastore M, Gitto S, Marra F. Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression. Cells 2021;10:2759. [PMID: 34685739 DOI: 10.3390/cells10102759] [Reference Citation Analysis]
9 Shojaie L, Iorga A, Dara L. Cell Death in Liver Diseases: A Review. Int J Mol Sci 2020;21:E9682. [PMID: 33353156 DOI: 10.3390/ijms21249682] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
10 Negi CK, Babica P, Bajard L, Bienertova-Vasku J, Tarantino G. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism 2021;126:154925. [PMID: 34740573 DOI: 10.1016/j.metabol.2021.154925] [Reference Citation Analysis]
11 Sharma M, Premkumar M, Kulkarni AV, Kumar P, Reddy DN, Rao NP. Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail. J Clin Transl Hepatol 2021;9:40-50. [PMID: 33604254 DOI: 10.14218/JCTH.2020.00055] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Mandorfer M, Simbrunner B. Prevention of First Decompensation in Advanced Chronic Liver Disease. Clin Liver Dis 2021;25:291-310. [PMID: 33838851 DOI: 10.1016/j.cld.2021.01.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kronborg TM, Ytting H, Hobolth L, Møller S, Kimer N. Novel Anti-inflammatory Treatments in Cirrhosis. A Literature-Based Study. Front Med (Lausanne) 2021;8:718896. [PMID: 34631742 DOI: 10.3389/fmed.2021.718896] [Reference Citation Analysis]
14 Zhang H, Zhou L, Zhou Y, Wang L, Jiang W, Liu L, Yue S, Zheng P, Liu H. Intermittent hypoxia aggravates non-alcoholic fatty liver disease via RIPK3-dependent necroptosis-modulated Nrf2/NFκB signaling pathway. Life Sci 2021;285:119963. [PMID: 34536498 DOI: 10.1016/j.lfs.2021.119963] [Reference Citation Analysis]
15 Moga L, Laroyenne A, Larrue H, Bureau C, Rautou PE. Patients with NAFLD do not have severe portal hypertension in the absence of cirrhosis. J Hepatol 2021;74:1269-70. [PMID: 33340573 DOI: 10.1016/j.jhep.2020.10.011] [Reference Citation Analysis]
16 Magusto J, Majdi A, Gautheron J. [Cell death mechanisms in non-alcoholic steatohepatitis]. Biol Aujourdhui 2020;214:1-13. [PMID: 32773025 DOI: 10.1051/jbio/2020002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Qu W, Ma T, Cai J, Zhang X, Zhang P, She Z, Wan F, Li H. Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies. Front Med (Lausanne) 2021;8:761538. [PMID: 34746195 DOI: 10.3389/fmed.2021.761538] [Reference Citation Analysis]
18 Kist M, Vucic D. Cell death pathways: intricate connections and disease implications. EMBO J 2021;40:e106700. [PMID: 33439509 DOI: 10.15252/embj.2020106700] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
19 Bai W, Al-Karaghouli M, Stach J, Sung S, Matheson GJ, Abraldes JG. Test-Retest Reliability and Consistency of HVPG and Impact on Trial Design: A Study in 289 Patients from 20 Randomized Controlled Trials. Hepatology 2021. [PMID: 34181770 DOI: 10.1002/hep.32033] [Reference Citation Analysis]
20 Attia SL, Softic S, Mouzaki M. Evolving Role for Pharmacotherapy in NAFLD/NASH. Clin Transl Sci 2021;14:11-9. [PMID: 32583961 DOI: 10.1111/cts.12839] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
21 Burra P, Becchetti C, Germani G. NAFLD and liver transplantation: Disease burden, current management and future challenges. JHEP Rep 2020;2:100192. [PMID: 33163950 DOI: 10.1016/j.jhepr.2020.100192] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
22 Weinberg EM, Curry MP, Frenette CT, Regenstein FG, Schiff ER, Goodman ZD, Robinson JM, Chan JL, Imperial JC, Reddy KR. Multicenter, Double-Blind, Randomized Trial of Emricasan in Hepatitis C-Treated Liver Transplant Recipients With Residual Fibrosis or Cirrhosis. Liver Transpl 2021;27:568-79. [PMID: 33164276 DOI: 10.1002/lt.25934] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Sanz-garcía C, Fernández-iglesias A, Gracia-sancho J, Arráez-aybar LA, Nevzorova YA, Cubero FJ. The Space of Disse: The Liver Hub in Health and Disease. Livers 2021;1:3-26. [DOI: 10.3390/livers1010002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
24 Kristensen H, Kimer N, Møller S. Indications and methods for measuring portal hypertension in cirrhosis. Scand J Gastroenterol 2022;:1-9. [PMID: 35514215 DOI: 10.1080/00365521.2022.2065889] [Reference Citation Analysis]
25 Lee YA, Friedman SL. Inflammatory and fibrotic mechanisms in NAFLD-Implications for new treatment strategies. J Intern Med 2021. [PMID: 34564899 DOI: 10.1111/joim.13380] [Reference Citation Analysis]
26 Roehlen N, Crouchet E, Baumert TF. Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells 2020;9:E875. [PMID: 32260126 DOI: 10.3390/cells9040875] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 24.5] [Reference Citation Analysis]
27 Guixé-muntet S, Zhu C, Xie W, Gracia-sancho J. Novel therapeutics for portal hypertension and fibrosis in chronic liver disease. Pharmacology & Therapeutics 2020;215:107626. [DOI: 10.1016/j.pharmthera.2020.107626] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
28 Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. JHEP Rep 2021;3:100316. [PMID: 34337369 DOI: 10.1016/j.jhepr.2021.100316] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Chen Y, Tian Z. Roles of Hepatic Innate and Innate-Like Lymphocytes in Nonalcoholic Steatohepatitis. Front Immunol 2020;11:1500. [PMID: 32765518 DOI: 10.3389/fimmu.2020.01500] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
30 Wang H, Mehal W, Nagy LE, Rotman Y. Immunological mechanisms and therapeutic targets of fatty liver diseases. Cell Mol Immunol 2021;18:73-91. [PMID: 33268887 DOI: 10.1038/s41423-020-00579-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
31 Vuppalanchi R, Noureddin M, Alkhouri N, Sanyal AJ. Therapeutic pipeline in nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 2021;18:373-92. [PMID: 33568794 DOI: 10.1038/s41575-020-00408-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
32 Barillé-Nion S, Lohard S, Juin PP. Targeting of BCL-2 Family Members during Anticancer Treatment: A Necessary Compromise between Individual Cell and Ecosystemic Responses? Biomolecules 2020;10:E1109. [PMID: 32722518 DOI: 10.3390/biom10081109] [Reference Citation Analysis]
33 Damiris K, Tafesh ZH, Pyrsopoulos N. Efficacy and safety of anti-hepatic fibrosis drugs. World J Gastroenterol 2020; 26(41): 6304-6321 [PMID: 33244194 DOI: 10.3748/wjg.v26.i41.6304] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
34 Li K, van Delft MF, Dewson G. Too much death can kill you: inhibiting intrinsic apoptosis to treat disease. EMBO J 2021;40:e107341. [PMID: 34037273 DOI: 10.15252/embj.2020107341] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Satiya J, Snyder HS, Singh SP, Satapathy SK. Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis. Transl Gastroenterol Hepatol 2021;6:60. [PMID: 34805582 DOI: 10.21037/tgh-20-247] [Reference Citation Analysis]
36 Parlati L, Régnier M, Guillou H, Postic C. New targets for NAFLD. JHEP Rep 2021;3:100346. [PMID: 34667947 DOI: 10.1016/j.jhepr.2021.100346] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Burra P, Bizzaro D, Gonta A, Shalaby S, Gambato M, Morelli MC, Trapani S, Floreani A, Marra F, Brunetto MR, Taliani G, Villa E; Special Interest Group Gender in Hepatology of the Italian Association for the Study of the Liver (AISF). Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Liver Int 2021;41:1713-33. [PMID: 33982400 DOI: 10.1111/liv.14943] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Garcia-Tsao G. Can We Rely on Changes in HVPG in Patients with Cirrhosis? Hepatology 2021;74:2945-7. [PMID: 34569630 DOI: 10.1002/hep.32159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Ratziu V, Francque S, Sanyal A. Breakthroughs in therapies for NASH and remaining challenges. J Hepatol 2022;76:1263-78. [PMID: 35589249 DOI: 10.1016/j.jhep.2022.04.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Mu LY, Li SQ, Tang LX, Li R. Efficacy and Safety of Emricasan in Liver Cirrhosis and/or Fibrosis. Clinics (Sao Paulo) 2021;76:e2409. [PMID: 34133478 DOI: 10.6061/clinics/2021/e2409] [Reference Citation Analysis]
41 Frenette C, Kayali Z, Mena E, Mantry PS, Lucas KJ, Neff G, Rodriguez M, Thuluvath PJ, Weinberg E, Bhandari BR, Robinson J, Wedick N, Chan JL, Hagerty DT, Kowdley KV; IDN-6556-17 Study Investigators. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis. J Hepatol 2021;74:274-82. [PMID: 33038432 DOI: 10.1016/j.jhep.2020.09.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
42 Drenth JP, Schattenberg JM. The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success. Expert Opinion on Investigational Drugs 2020;29:1365-75. [DOI: 10.1080/13543784.2020.1839888] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
43 Shen B, Lu LG. Efficacy and safety of drugs for nonalcoholic steatohepatitis. J Dig Dis 2021;22:72-82. [PMID: 33385317 DOI: 10.1111/1751-2980.12967] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
44 Veldhuijzen van Zanten D, Buganza E, Abraldes JG. The Role of Hepatic Venous Pressure Gradient in the Management of Cirrhosis. Clin Liver Dis 2021;25:327-43. [PMID: 33838853 DOI: 10.1016/j.cld.2021.01.002] [Reference Citation Analysis]
45 Maurel P, Prémaud A, Carrier P, Essig M, Barbier L, Rousseau A, Silvain C, Causse X, Debette-Gratien M, Jacques J, Marquet P, Salamé E, Loustaud-Ratti V. Evaluation of Longitudinal Exposure to Tacrolimus as a Risk Factor of Chronic Kidney Disease Occurrence Within the First-year Post-Liver Transplantation. Transplantation 2021;105:1585-94. [PMID: 32639405 DOI: 10.1097/TP.0000000000003384] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Sookoian S, Pirola CJ. Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology. Clin Mol Hepatol. 2020;26:461-475. [PMID: 32906228 DOI: 10.3350/cmh.2020.0136] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
47 Fallowfield JA, Jimenez-Ramos M, Robertson A. Emerging synthetic drugs for the treatment of liver cirrhosis. Expert Opin Emerg Drugs 2021;26:149-63. [PMID: 33856246 DOI: 10.1080/14728214.2021.1918099] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Padda J, Khalid K, Khedr A, Tasnim F, Al-Ewaidat OA, Cooper AC, Jean-Charles G. Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus. Cureus 2021;13:e17321. [PMID: 34557367 DOI: 10.7759/cureus.17321] [Reference Citation Analysis]
49 Dhani S, Zhao Y, Zhivotovsky B. A long way to go: caspase inhibitors in clinical use. Cell Death Dis 2021;12:949. [PMID: 34654807 DOI: 10.1038/s41419-021-04240-3] [Reference Citation Analysis]
50 Plassmeyer M, Alpan O, Corley MJ, Premeaux TA, Lillard K, Coatney P, Vaziri T, Michalsky S, Pang APS, Bukhari Z, Yeung ST, Evering TH, Naughton G, Latterich M, Mudd P, Spada A, Rindone N, Loizou D, Ulrik Sønder S, Ndhlovu LC, Gupta R. Caspases and therapeutic potential of caspase inhibitors in moderate-severe SARS CoV2 infection and long COVID. Allergy 2021. [PMID: 33993490 DOI: 10.1111/all.14907] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
51 Yenilmez B, Wetoska N, Kelly M, Echeverria D, Min K, Lifshitz L, Alterman JF, Hassler MR, Hildebrand S, DiMarzio C, McHugh N, Vangjeli L, Sousa J, Pan M, Han X, Brehm MA, Khvorova A, Czech MP. An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitis. Mol Ther 2021:S1525-0016(21)00578-5. [PMID: 34774753 DOI: 10.1016/j.ymthe.2021.11.007] [Reference Citation Analysis]
52 Odagiri N, Matsubara T, Sato-Matsubara M, Fujii H, Enomoto M, Kawada N. Anti-fibrotic treatments for chronic liver diseases: The present and the future. Clin Mol Hepatol 2021;27:413-24. [PMID: 33317250 DOI: 10.3350/cmh.2020.0187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Kostallari E, Valainathan S, Biquard L, Shah VH, Rautou PE. Role of extracellular vesicles in liver diseases and their therapeutic potential. Adv Drug Deliv Rev 2021;175:113816. [PMID: 34087329 DOI: 10.1016/j.addr.2021.05.026] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
54 Kumar V, Xin X, Ma J, Tan C, Osna N, Mahato RI. Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis. Adv Drug Deliv Rev 2021;:113888. [PMID: 34314787 DOI: 10.1016/j.addr.2021.113888] [Reference Citation Analysis]
55 Tacke F, Weiskirchen R. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention. Ann Transl Med 2021;9:729. [PMID: 33987427 DOI: 10.21037/atm-20-4354] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
56 Albhaisi S, Noureddin M. Current and Potential Therapies Targeting Inflammation in NASH. Front Endocrinol (Lausanne) 2021;12:767314. [PMID: 34925237 DOI: 10.3389/fendo.2021.767314] [Reference Citation Analysis]
57 Gibert-Ramos A, Sanfeliu-Redondo D, Aristu-Zabalza P, Martínez-Alcocer A, Gracia-Sancho J, Guixé-Muntet S, Fernández-Iglesias A. The Hepatic Sinusoid in Chronic Liver Disease: The Optimal Milieu for Cancer. Cancers (Basel) 2021;13:5719. [PMID: 34830874 DOI: 10.3390/cancers13225719] [Reference Citation Analysis]
58 Barberá A, Raurell I, García-Lezana T, Torres-Arauz M, Bravo M, Hide D, Gil M, Salcedo MT, Genescà J, Martell M, Augustin S. Steatosis as main determinant of portal hypertension through a restriction of hepatic sinusoidal area in a dietary rat nash model. Liver Int 2020;40:2732-43. [PMID: 32770818 DOI: 10.1111/liv.14632] [Cited by in F6Publishing: 1] [Reference Citation Analysis]